Sentences with phrase «advanced bladder cancer»

At present there is no standard second - line therapy for advanced bladder cancer.

To increase public awareness about bladder cancer; to advance bladder cancer research; and to provide educational and support services for the bladder cancer community.

Based primarily on clinical trials led by Arjun V. Balar, MD, assistant professor of medicine and director of the Genitourinary Medical Oncology Program, the FDA approved atezolizumab (Tecentriq ®) and pembrolizumab (Keytruda ®) as first - line treatments for these particularly frail patients with advanced bladder cancer in early 2017.

It represents a real advance in the second - line treatment of advanced bladder cancer because pembrolizumab is the first therapy to show a significant survival advantage over chemotherapy for these patients.

Through her Clinical Team Grant, Dr. Bhardwaj and Sacha Gnjatic, Ph.D., are investigating the relationship between checkpoint immunotherapy, chemotherapy, and mutations in advanced bladder cancer, to guide vaccine development and inform combination treatment approaches.

ZURICH (Reuters)- Roche's Tecentriq immuno - oncology drug failed a late - stage follow - up trial against advanced bladder cancer, the Swiss drugmaker said on Wednesday, raising questions about whether regulators could scale back their approval of the medicine.

U.S. health regulators on Tuesday granted accelerated approval for Pfizer Inc's immuno - oncology drug Bavencio to treat advanced bladder cancer, marking the second approval in less than two months for the treatment developed along with Germany's Merck KGaA.

Removal of the bladder, or radical cystectomy (RC), is an effective treatment for locally advanced bladder cancer, but complications occur in as many as 66 % of patients.

United Kingdom About Blog The author has Terminal Advanced Bladder Cancer and as a mum to four children you can imagine her devastation.

«Treatment for advanced bladder cancer is limited to surgery and chemotherapy.

The firm had even more positive results to present at the convention, announcing that Tecentriq shrunk tumors in 24 % of advanced bladder cancer patients who couldn't use standard chemotherapy in a mid-stage trial.

«We believe that Tecentriq will continue to play an important role in the treatment for people with advanced bladder cancer, and will discuss these data with health authorities,» a company spokesman said on Wednesday.

These results support the use of pembrolizumab as the new standard of care for advanced bladder cancer,» concluded Dr Necchi.

The FDA granted accelerated approval to avelumab (Bavencio, EMD Serono, Inc.), a checkpoint immunotherapy that targets the PD - 1 pathway, as a second - line treatment for advanced bladder cancer.

Based primarily on clinical trials led by Arjun V. Balar, MD, assistant professor of medicine and director of the Genitourinary Medical Oncology Program at Perlmutter Cancer Center, the FDA in early 2017 approved atezolizumab (Tecentriq ®) and pembrolizumab (Keytruda ®) as first - line treatments for these particularly frail patients with advanced bladder cancer.

As recently as 2016, when patients with advanced bladder cancer were too medically frail to take the standard - of - care chemotherapy agent cisplatin, oncologists had no effective alternatives to offer.